Qiagen NV (QGEN)

32.87
0.23 0.70
NASDAQ : Services
Prev Close 32.64
Open 32.77
Day Low/High 32.70 / 32.88
52 Wk Low/High 19.94 / 28.53
Volume 151.64K
Avg Volume 833.30K
Exchange NASDAQ
Shares Outstanding 227.66M
Market Cap 7.46B
EPS 0.30
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAN, CR, CVLT, CWCO, GPRK, KMB, MDLZ, MVC, OPB, POL, PW, RMBS, SNY Downgrades: ACOR, AKR, FCCY, NRZ, QGEN, SSY, SWFT, TBBK, WRI Initiations: UA Read on to get TheStreet Quant Ratings' detailed report:

New Research Suggests Potential For Additional Clinical Utility Of QIAGEN's QuantiFERON-TB Gold Plus

New Research Suggests Potential For Additional Clinical Utility Of QIAGEN's QuantiFERON-TB Gold Plus

Findings indicate increased specificity in low-risk populations and potential for monitoring tuberculosis treatment

QIAGEN Expands Liquid Biopsy Pipeline With AR-V7 Test In Prostate Cancer

QIAGEN Expands Liquid Biopsy Pipeline With AR-V7 Test In Prostate Cancer

Exclusive license to RNA biomarker from The Johns Hopkins University clears path to commercialization

QIAGEN Joins CANCER-ID Consortium For Liquid Biopsy Workflows

QIAGEN Joins CANCER-ID Consortium For Liquid Biopsy Workflows

Public-private partnership aims to standardize and clinically validate blood-based biomarkers

QIAGEN Launches First FDA-cleared JAK2 Test For Certain Type Of Leukemia

QIAGEN Launches First FDA-cleared JAK2 Test For Certain Type Of Leukemia

New biomarker test - the fifth QIAGEN oncology test with FDA clearance in the U.S. - designed to aid diagnosis of patients suspected of having Polycythemia Vera form of blood cancer

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

Cytokinetics, Achillion and Qiagen were among the biotech stock movers in premarket trading on Thursday.

QIAGEN's QuantiFERON-TB Test Wins Tender For Testing Of Republic Of Korea Armed Forces Recruits

QIAGEN's QuantiFERON-TB Test Wins Tender For Testing Of Republic Of Korea Armed Forces Recruits

Selected for screening of 340,000 recruits in 2017 as part of national TB control strategy

QIAGEN Announces Adjustment Of Conversion Ratio Under Its 0.375% Senior Unsecured Convertible Notes Due 2019 (ISIN XS1046477235)

QIAGEN Announces Adjustment Of Conversion Ratio Under Its 0.375% Senior Unsecured Convertible Notes Due 2019 (ISIN XS1046477235)

Adjustment of conversion ratio under 0.375% Senior Unsecured Convertible Notes due 2019 due to reduction in number of shares outstanding and direct capital repayment to shareholders

QIAGEN Announces Adjustment Of Conversion Ratio Under Its 0.375% Senior Unsecured Convertible Notes Due 2019 (ISIN XS1046477235)

QIAGEN Announces Adjustment Of Conversion Ratio Under Its 0.375% Senior Unsecured Convertible Notes Due 2019 (ISIN XS1046477235)

Adjustment of conversion ratio under 0.375% Senior Unsecured Convertible Notes due 2019 due to reduction in number of shares outstanding and direct capital repayment to shareholders

QIAGEN Announces Details For Completion Of Approximately $250 Million Synthetic Share Repurchase

QIAGEN Announces Details For Completion Of Approximately $250 Million Synthetic Share Repurchase

Adjustment to capital structure through reduction in number of shares outstanding and direct capital repayment set for completion in January 2017

QIAGEN Enhances Bioinformatics Portfolio With Acquisition Of OmicSoft

QIAGEN Enhances Bioinformatics Portfolio With Acquisition Of OmicSoft

Powerful multi-omics data management solution and highly curated 'omics' data sets complement QIAGEN's industry-leading interpretation solutions

QIAGEN Announces Comprehensive Range Of Enhancements For GeneReader NGS System

QIAGEN Announces Comprehensive Range Of Enhancements For GeneReader NGS System

Launch of new QIAact gene panels and customized panels service complemented by performance upgrades that further differentiate first Sample to Insight NGS sequencing solution

QIAGEN Submits QuantiFERON®-TB Gold Plus For U.S. Regulatory Approval

QIAGEN Submits QuantiFERON®-TB Gold Plus For U.S. Regulatory Approval

U.S. submission builds on 2016 launch of fourth-generation test in more than 60 countries and already used in more than 600,000 people to date

QIAGEN Welcomes New Evidence-Based Tuberculosis Testing Guidelines From U.S. Professional Societies

QIAGEN Welcomes New Evidence-Based Tuberculosis Testing Guidelines From U.S. Professional Societies

New guidelines recommend broader use of modern blood TB tests like QuantiFERON-TB Gold over the 100-year-old tuberculin skin test

QIAGEN's GeneReader NGS System Streamlines Data Management For Labs

QIAGEN's GeneReader NGS System Streamlines Data Management For Labs

New middleware co-developed with Genohm ensures full chain of custody from Sample to Insight and integrates with most LIMS systems

QIAGEN GeneReader NGS System To Relaunch In U.S. Market

QIAGEN GeneReader NGS System To Relaunch In U.S. Market

New improved chemistry for first Sample to Insight next-generation sequencing solution to be made available to first customers in December 2016

QIAGEN Shareholders Approve Return Of Approximately $250 Million In Cash To Shareholders Via Synthetic Share Repurchase

QIAGEN Shareholders Approve Return Of Approximately $250 Million In Cash To Shareholders Via Synthetic Share Repurchase

Adjustment to capital structure through reduction in number of shares outstanding and direct capital repayment to shareholders expected to be completed in January 2017

QIAGEN Launches QIAscout For Single-cell Isolation

QIAGEN Launches QIAscout For Single-cell Isolation

Compact, versatile and yet very affordable instrument provides unique front-end in workflows for molecular analysis of individual cells

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

Quest and IBM are rolling out a genomic sequencing service powered by Big Blue's Watson supercomputer.